This article contains online-exclusive supplemental material for Malik's article entitled, "Allogenic Versus Autologous Stem-Cell Therapy."
Nafees Malik
Advertisement
Articles by Nafees Malik
The author discusses potential manufacturing costs & challenges of allogeneic & autologous stem-cell therapy.
Eighty drugs will lose patent protection between 2007 and 2011.
Advertisement
Latest Updated Articles
Supplementary Material for Allogeneic Versus Autologous Stem-Cell Therapy: Manufacturing Costs and Commercialization StrategiesPublished: July 1st 2012 | Updated:
Allogeneic Versus Autologous Stem-Cell TherapyPublished: July 1st 2012 | Updated:
Has the Era of Blockbuster Drugs Come to an End?Published: December 1st 2007 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
